Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

NCT06814496 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT06814496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06814496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3
Lead sponsor
University of Arizona
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 8, 2025
Completion date
May 31, 2030
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervical cancer, esthesioneuroblastoma, glioblastoma multiforme, large cell neuroendocrine carcinoma of the lung, medullary thyroid cancer, melanoma, merkel cell carcinoma, non small cell lung cancer, sinonasal undifferentiated carcinoma, testicular cancer